Dr. Lisa N. Gervin, MD

Dr. Gervin practices at Mills-Peninsula Medical Center in Burlingame, California, part of Sutter Health.

Dr. Gervin's NPI, 1962425157, was assigned on July 26, 2006. Dr. Gervin graduated from Stanford University School Of Medicine in 1995. Dr. Gervin holds Florida license ME165140.

Dr. Gervin's primary practice is Mills-Peninsula Medical Center, at 1501 Trousdale Drive, Burlingame, CA 94010 in San Mateo County. The practice phone is (650) 696-5400.

Dr. Gervin's primary practice is Mills-Peninsula Medical Center in Burlingame, California, part of Sutter Health. The medical group on file is Palo Alto Foundation Medical Group.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gervin practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Gervin's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Gervin is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Gervin's licenses on file in 2 states: Florida and California.

Dmand AI lists acid reflux, alzheimer's disease, chronic diabetes, chronic hypertension, coronary artery disease, diabetic emergency, high cholesterol and insomnia among the conditions Dr. Gervin treats.

CMS data shows 68 Medicare services from Dr. Gervin across 2 procedure codes in 2024, all of them office visits, for 50 Medicare patients. Medicare paid $5,978 for them. Every service was in an office.

CMS counts 50 Medicare patients who saw Dr. Gervin in 2024. The largest group is 65 to 74, with 27 patients. 74% of them have high cholesterol, and 62% have high blood pressure. Their average risk score is 1.13, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Gervin's median patient age at 54, with 62% women.

In 2024, Dr. Gervin wrote 2,025 Medicare Part D claims for 300 patients. 87% of them were for generic drugs. CMS names the drug for 1,456 of them, across 46 drugs with 11 or more claims each, at $118,770 in total drug cost. In 2023, CMS named 815 claims across 32 drugs.

Dr. Gervin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gervin as offering telehealth.

Dmand AI links 1 paper to Dr. Gervin.

CMS Open Payments shows 6 general payments to Dr. Gervin from 3 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Exact Sciences Corporation paid the most, $44.

Dr. Gervin graduated from Stanford University School Of Medicine in 1995.

Dr. Gervin is in network with 10 carriers, including Elevance, Aetna and United Healthcare. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.